1375469-38-7

Basic information

• Product Name: BAY-1082439
• Synonyms: BAY-1082439;BAY 2439;N-[8-[[(2R)-2-Hydroxy-3-(morpholin-4-yl)propyl]oxy]-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]-2-methylpyridine-3-carboxamide;(R)-N-(8-(2-hydroxy-3-morpholinopropoxy)-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-2-methylnicotinamide
• CAS NO: 1375469-38-7
• Molecular Formula: C25H30N6O5
• Molecular Weight: 494.5429
• Mol File: 1375469-38-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BAY-1082439(CAS DataBase Reference)
• NIST Chemistry Reference: BAY-1082439(1375469-38-7)
• EPA Substance Registry System: BAY-1082439(1375469-38-7)

Safety Data

• Hazardous Substances Data: 1375469-38-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
BAY-1082439 is used as an anticancer agent for its ability to inhibit the PI3K delta and gamma isoforms, which are often dysregulated in various cancers. This inhibition can lead to the suppression of tumor growth and progression, making it a potential therapeutic option for cancer treatment.
Used in Anti-Inflammatory Applications:
BAY-1082439 is used as an anti-inflammatory agent due to its inhibitory effects on the PI3K delta and gamma isoforms, which are involved in inflammatory responses. By targeting these enzymes, BAY-1082439 may help reduce inflammation and alleviate symptoms associated with inflammatory diseases.
Used in Drug Development:
BAY-1082439 is used as a lead compound in the development of new cancer and anti-inflammatory therapies. Its selective inhibition of PI3K delta and gamma, along with its favorable pharmacokinetic properties and tolerability, make it a valuable starting point for the design and optimization of novel therapeutic agents targeting these key enzymes.

Upstream product

• 110-91-8 morpholine 
• 881-68-5 vanillin acetate 
• 2698-69-3 4-formyl-2-methoxy-3-nitrophenyl acetate 
• 2450-26-2 2-nitrovanillin 
• 2450-27-3 4-(benzyloxy)-3-methoxy-2-nitrobenzaldehyde 
• 887202-50-8 3-(benzyloxy)-6-(4,5-dihydro-1H-imidazol-2-yl)-2-methoxyaniline 
• 1032570-69-6 8-(benzyloxy)-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-amine 
• 65719-09-7 methyl 2-methylnicotinate 
• 3222-56-8 2-methylnicotinic acid 
• 1721-26-2 ethyl 2-methyl nicotinate 
• 1375468-81-7 4-{[(4R)-2-oxido-1,3,2-dioxathiolan-4-yl]methyl}morpholine hydrochloride 
• 222021-47-8 (2R)-3-(morpholin-4-yl)propane-1,2-diol 

Relevant articles and documents

2-methyl nicotinate as well as preparation method and application thereof

The invention relates to 2-methyl nicotinate as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) reacting 1, 1, 3, 3-tetramethoxypropane or 1, 1, 3, 3-tetraethoxypropane under the action of acid to obtain a compound B; (2) reacting the compound B and beta-aminocrotonate in a first organic solvent to obtain 2-methyl nicotinate, wherein no foul acrolein is used in the process, the safety coefficient of production is effectively improved, the reaction raw materials are easy to obtain, the conditions are mild, the operation is simple, the yield is greater than 65%, the product purity reaches 98% or above, and the method is suitable for industrial production and has a wide application prospect. The obtained product can be used as an intermediate for synthesizing 2-methyl nicotinic acid, and can be used for synthesizing medicines.

SYNTHESIS OF PI3K INHIBITOR AND SALTS THEREOF

The present invention relates to a novel method of preparing a compound of formula (I) or salt thereof, to novel intermediate compounds, to the use of said novel intermediate compounds for the preparation of said compound of formula (I) or salt thereof an

SYNTHESIS OF PI3K INHIBITOR AND SALTS THEREOF

The present invention relates to a novel method of preparing a compound of formula (I) or salt thereof, to novel intermediate compounds, to the use of said novel intermediate compounds for the preparation of said compound of formula (I) or salt thereof. T

AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS

This invention relates to novel 2,3-dihydroimidazo[1,2 -c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/ or angiogenesis disorders, as a sole agent or in combination with other active ingredients